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Available online 23 December 2018Background: Risk stratiﬁcation is crucial to improve tailored therapy in patients with suspected coronary artery
disease (CAD). This study investigated the ability of targeted proteomics to predict presence of high-risk plaque
or absence of coronary atherosclerosis in patients with suspected CAD, deﬁned by coronary computed tomogra-
phy angiography (CCTA).
Methods: Patients with suspected CAD (n= 203) underwent CCTA. Plasma levels of 358 proteins were used to
generate machine learning models for the presence of CCTA-deﬁned high-risk plaques or complete absence of
coronary atherosclerosis. Performance was tested against a clinical model containing generally available clinical
characteristics and conventional biomarkers.
Findings:A total of 196 patientswith analyzable protein levels (n=332)was included for analysis. A subset of 35
proteinswas identiﬁed predicting the presence of high-risk plaques. The developedmachine learningmodel had
fair diagnostic performance with an area under the curve (AUC) of 0·79 ± 0·01, outperforming prediction with
generally available clinical characteristics (AUC = 0·65 ± 0·04, p b 0·05). Conversely, a different subset of 34
proteins was predictive for the absence of CAD (AUC= 0·85± 0·05), again outperforming prediction with gen-
erally available characteristics (AUC = 0·70 ± 0·04, p b 0·05).
Interpretation: Using machine learning models, trained on targeted proteomics, we deﬁned two complementary
protein signatures: one for identiﬁcation of patients with high-risk plaques and one for identiﬁcation of patients
with absence of CAD. Both biomarker subsetswere superior to generally available clinical characteristics and con-
ventional biomarkers in predicting presence of high-risk plaque or absence of coronary atherosclerosis. These
promising ﬁndings warrant external validation of the value of targeted proteomics to identify cardiovascular
risk in outcome studies.
Fund: This study was supported by an unrestricted research grant fromHeartFlow Inc. and partly supported by a
European Research Area Network on Cardiovascular Diseases (ERA-CVD) grant (ERA CVD JTC2017, OPERATION).
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Research in context
Evidence before this study
Although current guidelines advice to use risk assessment in pa-
tients with stable coronary artery disease, traditional risk models
have only moderate prognostic value for future events. Over the
last decades, numerous individual inflammatory plasma protein
have been linked to the pathophysiology of atherosclerosis in ani-
mal models and clinical studies. However, studies on the use of
large scale proteomics to identify patients with high-risk coronary
plaques as defined by coronary CT angiography are lacking. We
performed a PubMed search for articles published up to April 19,
2018, using the following search terms: “biomarker” AND (“coro-
nary CT” OR “CCTA”). This search yielded 25 results. However,
none of these studies met our inclusion criteria. Subsequently,
we performed a second PubMed search for articles reporting on
the use of proteomics to identify patients with stable coronary ar-
tery disease at risk for future events. The following search terms
were used: “proteomics” AND “coronary artery disease” AND
(“events” or “MACE” or “cardiac events”). This search yielded23 re-
sults, of which only one study reported on the use of proteomics
to identify patients at risk for coronary events. This study used a
large-scale analysis of 1130 plasma proteins to derive and validate
a score that was moderately predictive for cardiovascular out-
come. Although the concept of using proteomics to identify pa-
tients with stable coronary artery disease at risk for future
events seems promising, supporting data remains limited.
Added value of this study
Using state-of-the-art machine learning models, trained on
targeted plasma proteomics, we defined two complementary pro-
tein signatures: one for the identification of patients with high-risk
coronary lesions and one for the identification of patients with ab-
sence of coronary atherosclerosis on CCTA. Both biomarker sub-
sets were shown to be superior to generally available clinical
characteristics and conventional biomarkers in predicting pres-
ence of high-risk plaque or absence of coronary atherosclerosis.
These promising findings further support the potential of targeted
proteomics to identify high risk patients.
Implications of all available evidence
The high diagnostic accuracy of the identiﬁed protein signa-
tures for high-risk lesions and the absence of coronary atheroscle-
rosis in the present study, implicates that there could be potential
for the use of proteomics for risk stratiﬁcation in clinical practice.
Identiﬁcation of patients with high-risk lesions can help guide the
use of expensivemedication to the highest risk group. Conversely,
identiﬁcation of referred patients without coronary atherosclero-
sis can help avoid overtreatment. Importantly, to conﬁrm the
value of the two protein signatures, prospective external valida-
tion in outcome studies is warranted. If conﬁrmed, this may her-
ald the introduction of targeted proteomics in the cardiovascular
arena.
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Coronary CT angiography (CCTA) is a commonly used non-invasive
imagingmodality for the diagnostic work-up of patientswith suspected
coronary artery disease (CAD). In addition to the evaluation of stenosis
grade, CCTA allows in-vivo phenotyping of plaque morphology andidentiﬁcation of high-risk plaques, i.e. plaques with a high likelihood
of causing an acute coronary event [1–3]. Although current guidelines
emphasize the need for adequate risk-assessment in suspected CAD
patients [4], traditional risk stratiﬁcation, using generally available clin-
ical risk factors, plasma lipid levels and other conventional biomarkers
(troponin T, NT-proBNP, and CRP) have only modest predictive value
for the presence of coronary atherosclerosis and the occurrence of
events [5–9]. This underscores the need for novel biomarkers predictive
for coronary atherosclerosis. In the search for these biomarkers, several
individual inﬂammatory plasma proteins have been linked to the path-
ophysiology of atherosclerosis [10]. Recently, the development of prox-
imity extension assays (PEA) has enabled simultaneous measurement
of large numbers of proteins using only one microliter of plasma,
thereby enabling the use of proteomics in large clinical populations
[11]. In parallel, the introduction of machine learning has emerged as
a highly effective method for prediction [12]. This study therefore
aimed to investigate the ability of a large set of 358 biomarkers to iden-
tify either CCTA-derived high-risk coronary lesions or absence of coro-
nary atherosclerosis in patients with suspected CAD using machine
learning. Additionally, the added value of these biomarker panels to




The current report is a sub-study of the PACIFIC trial and details re-
garding the study design have been described previously [13]. The
study population consisted of 208 consecutively selected out-patients
with stable new-onset chest pain and suspected CAD. All patients
were aged 40 years and above andhad intermediate pre-test probability
for CAD as deﬁned by Diamond and Forrester criteria. Major exclusion
criteria were renal failure (i.e. eGFR b45 mL/min), history of COPD or
chronic asthma, a prior history of CAD, atrial ﬁbrillation, and second or
third degree AV block. All patients underwent a two day protocol,
including CCTA on day 1 and blood sampling on day 2 (within
2 weeks). Both CCTA imaging and laboratory sampling were performed
as dictated by the study protocol and independent of clinical status.
For the current analysis all patients with CCTA images eligible for
plaque analysis and with available laboratory samples were included
(n=203). The studyprotocolwas approved by theMedical Ethics Com-
mittee of the VU University Medical Center and written informed con-
sent was obtained.
2.2. Proteomics analysis
Patients were fasting for at least 12 h, resting for at least 10 min and
sitting in a upright position before blood samplingwas performed. After
blood samples were collected, EDTA plasma samples were stored at
−80 °C for a mean period of 4·1 ± 0·8 years before analysis. None of
the samples were thawed and refrozen before analysis. After comple-
tion of the study, available EDTA plasma samples of the complete cohort
were shipped to Olink Proteomics AB (Uppsala, Sweden) for analysis.
Using PEA technology, levels of 358 proteins were measured (Supple-
mentary Table 1). The PEA technology has been described previously
[11]. In brief, pairs of oligonucleotide-labeled antibody probes bind to
their targeted protein, and if the two probes are brought in close
proximity the oligonucleotides will hybridize in a pair-wise manner.
The addition of a DNA polymerase leads to a proximity-dependent
DNA polymerization event, generating a unique PCR target sequence.
The resulting DNA sequence is subsequently detected and quantiﬁed
using a microﬂuidic real-time PCR instrument (Biomark HD, Fluidigm
Corporation, CA, USA). Data is quality controlled and normalized using
an internal extension control and an inter-plate control, to adjust for
intra- and inter-run variation. The extension control is composed of an
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control that is added to every sample well. It will adjust for technical
variation introduced in the extension step and hence reduce intra-
assay variability. The ﬁnal assay read-out is presented in Normalized
Protein eXpression (NPX) values, which is an arbitrary unit on a log2-
scale where high values correspond to higher protein expressions.
Patients with samples that failed quality control were excluded. Fur-
thermore, proteins were excluded from analysis if N20% of individual
measurements were below the lower limit of detection. When b20%
was below lower limit of detection, missing values were replaced by
the limit of detection divided by two. All assay validation data for the
proteins in the Cardiovascular II, Cardiovascular III, Cardiometabolic
and Inﬂammation panels (detection limits, intra- and inter-assay preci-
sion data, accuracy, etc) are available onmanufacturer's website (www.
olink.com). Across all 92 assays in Cardiovascular II, the mean intra-
assay (within-run) and inter-assay (between-run) variations expressed
as coefﬁcients of variation are reported to be 9·1% and 11·7%. For assays
in the Cardiovascular III panel intra- and inter-assay variation are re-
ported to be 8·1% and 11·4% respectively, for assays in the Inﬂamma-
tion panel 7% and 18% respectively, and for assays in the
Cardiometabolic panel 12·9% and 9·5% respectively.
2.3. CCTA acquisition and plaque analysis
Patient preparation, acquisition of CCTA, methodology for plaque
analysis, and coronary artery calcium scoring are described in detail in
the Supplementary Methods. In short, patients underwent CCTA on a
256-slice CT-scanner (Brilliance iCT, Philips Healthcare, Best, the
Netherlands) with prospective ECG-gating (Step & Shoot Cardiac,
Philips Healthcare) at 75% of the R-R interval. Absence of CAD was
deﬁned as a coronary calcium score of zero and CT angiography
showing no coronary plaques. Coronary lesions were analyzed for the
following adverse plaque characteristics: positive remodeling, low at-
tenuation plaque, spotty calciﬁcation, and napkin ring sign. A high-risk
coronary lesion was deﬁned as a lesion with ≥2 adverse plaque charac-
teristics [14].
2.4. Descriptive statistics
Descriptive statistical analyses were performed using the SPSS soft-
ware package (version 20.0.0, IBM SPSS Statistics, Armonk, New York).
Continuous variables were tested for normal distribution. Normal
distributed continuous variables are presented as mean ± SD. Non-
normal distributed variables are presented asmedianwith interquartile
range. Categorical variables are presented as frequencies with percent-
ages and compared with the chi-square test or Fisher's exact test were
applicable. Variables were compared with the chi-square test for
categorical variables and by independent samples t-test for normal
distributed continuous variables. Log transformation was applied to
NT-proBNP and hs-Troponin T to enable parametric testing.
2.5. Statistical machine learning analysis
We identiﬁed two panels of biomarkers that allowed accurate dis-
crimination among 1) patients with high-risk vs. patients without
high-risk plaques and 2) patients with presence vs. patients without
coronary atherosclerosis, as deﬁned by CCTA. Our multivariate analysis
is described in detail in the SupplementaryMethods. In brief, we used a
combination of deep stacking generalization framework [15] with mul-
tiple levels of gradient boosting classiﬁers [16] to improve prediction
accuracy. The strategy employed by our algorithm is to utilize sub-
sampling and model stacking to control over-ﬁtting and improve
prediction. The method allows learning of non-linear multivariate rela-
tionships among the proteins and is applicable to structured and high-
dimensional data.We conducted a rigorous stability selection procedure [17] to ensure
reliability of the biomarker signatures. A randomization test [18] was
conducted to evaluate statistical validity of the results. We followed a
standard procedure where the outcome variable (e.g. presence of
high-risk plaque) was randomly reshufﬂed while the corresponding
protein proﬁles were kept intact. This was repeated up to 100 times
and Receiver-Operating-Characteristics Area-Under-Curve (ROC AUC)
scores were computed each time. Predictive value of the biomarker
model for the presence of high-risk plaques was tested against a clinical
model that comprised generally available clinical characteristics and
conventional biomarkers (referred to as clinical model), i.e. age, sex,
total cholesterol, HDL cholesterol, diabetes, systolic blood pressure, cur-
rent smoking, family history, BMI, statin use, eGFR, high-sensitive tropo-
nin T, NT-proBNP, and CRP levels. Additionally, a third model (referred
to as combined model) was computed in which all variables from the
clinical model and the predictive biomarkers from the biomarker
model were included. This model was tested against the clinical model
to establish the incremental predictive value of the identiﬁed biomarker
panel for high-risk plaque. Subsequently, these three models (clinical,
biomarker, and combined) were also computed for the identiﬁcation
of patients with absence of CAD.
Troponin and NT-proBNP values below limit of detection were re-
placed by the lower limit of detection divided by two. Since in 150 sub-
jects (77%) CRP levelswere below the limit of detection (2·5mg/L), CRP
was dichotomized for analysis, with the limit of detection as threshold.2.6. Data sharing
All individual participant data that underlie the results reported in
this article will be made freely available, after de-identiﬁcation, at
Mendeley Data (http://dx.doi.org/10.17632/gdfvxvr7f2.1). There are
no restrictions to obtaining the data.3. Results
3.1. Study population
An initial 203 patients with interpretable CCTA images and available
laboratory samples was evaluated for inclusion. After laboratory analy-
sis was performed, 7 patients were excluded due to failure to pass the
quality control of the proteomics measurements. This resulted in a
ﬁnal study population of 196 patients. The baseline characteristics of
these patients are provided in Table 1.3.2. Coronary CT angiography
CCTA showed one or more coronary lesions with N50% stenosis in
143 (73·0%) patients. A high-risk coronary lesion was observed in 44
(22·4%) patients, whereas 26 (13·3%) patients had complete absence
of CAD. An overview of CCTA results is given in Table 2. Baseline charac-
teristics stratiﬁed by patient groups, i.e. patients with and without
high-risk plaque and patients with and without CAD, are presented in
Table 1.
There were some signiﬁcant differences in baseline characteristics
between patients with and without high-risk plaque and between
patients with and without CAD (Table 1). Typical chest pain, beta
blocker use, and male gender were more frequent and creatinin and
hs-Troponin T levels were signiﬁcantly higher in the high-risk plaque
vs non-high-risk plaque group (p b .05 for all). Patients without CAD
were younger, more frequently female, less likely to use aspirin and to
suffer from hypertension as compared to patients with CAD (p b .05
for all). Furthermore, patients without CAD had lower systolic blood
pressure and Framingham Risk Score (p b .05 for all).
Table 1
Baseline characteristics.
Demographics Overall (n= 196) Non-HRP (n= 152) HRP (n= 44) p-value No CAD (n= 26) CAD (n= 170) p-value
Age, years 58 ± 8 58 ± 9 59 ± 8 0.35 52 ± 6 59 ± 8 b0.001
Male 126 (64%) 90 (59%) 36 (82%) 0.006 12 (46%) 114 (67%) 0.04
Body mass index 27 ± 4 27 ± 4 27 ± 3 0.85 27 ± 4 27 ± 4 0.63
Risk factors – no (%)
DM type II 30 (15%) 24 (16%) 6 (14%) 0.73 2 (8%) 28 (17%) 0.38
Hypertension 90 (46%) 74 (49%) 16 (36%) 0.15 7 (27%) 83 (49%) 0.04
Hyperlipidaemia 75 (38%) 56 (37%) 19 (43%) 0.45 8 (31%) 67 (39%) 0.40
Current smoker 40 (20%) 28 (18%) 12 (27%) 0.20 6 (23%) 34 (20%) 0.72
Family history 102 (52%) 80 (53%) 22 (50%) 0.76 14 (54%) 88 (52%) 0.84
Type of chest pain – no (%)
Between groups 0.005 0.13
Typical angina 68 (35%) 44 (29%) 24 (55%) 0.002 8 (31%) 60 (35%) NA
Atypical angina 76 (39%) 62 (41%) 14 (32%) 0.28 7 (27%) 69 (41%) NA
Non-speciﬁc chest discomfort 52 (27%) 46 (30%) 6 (14%) 0,03 11 (42%) 41 (24%) NA
Laboratory tests
TC, mmol/La 4·6 ± 1·1 4·5 ± 1·0 4·7 ± 1·3 0.33 4·5 ± 1.0 4·6 ± 1.1 0.57
LDL-C, mmol/La 2·5 ± 0·9 2·5 ± 0·9 2·6 ± 1·0 0.39 2·4 ± 1.1 2·5 ± 0.9 0.41
HDL-C, mmol/La 1·4 ± 0·5 1·4 ± 0·5 1·3 ± 0·4 0.14 1·4 ± 0.3 1·4 ± 0.5 0.79
Triglycerides, mmol/La 1·5 ± 0·9 1·5 ± 0·8 1·7 ± 1·2 0.33 1·4 ± 0.6 1·5 ± 0.9 0.37
hs-Troponin T, ng/La 5·0 [4·0–8·3] 5·0 [3·0–8·0] 7·0 [4·0–9·0] 0.044 4·0 [3·0–7·0] 6·0 [4·0–9·0] 0.05
NT-proBNP, ng/La 67 [40–135] 65 [40–132] 69 [42–182] 0.35 59 [34–115] 69 [42–136] 0.42
Creatinin, μmol/L 72·8 ± 13·7 71·6 ± 13·4 76·8 ± 13·9 0.03 72·5 ± 15·0 72·8 ± 13·5 0.93
eGFR b60 mL/min, no (%) 5 (3%) 4 (3%) 1 (2%) 1.00 1 (4%) 4 (2%) 0.51
CRP ≥ 2.5 mg/L, no (%) 36 (18%) 28 (18%) 8 (18%) 0.97 5 (19%) 31 (18%) 1.00
Medication use – no (%)
Statin 151 (77%) 112 (74%) 39 (89%) 0.04 18 (69%) 133 (78%) 0.31
Acetylsalicylic acid 175 (89%) 133 (88%) 42 (96%) 0.17 20 (77%) 155 (91%) 0.03
Betablocker 126 (64%) 90 (59%) 36 (82%) 0.006 16 (62%) 110 (65%) 0.75
ACE-inhibitor/ARB 73 (37%) 61 (40%) 12 (27%) 0.12 6 (23%) 67 (39%) 0.11
Other
SBP, mm Hg 143 ± 20 143 ± 19 144 ± 21 0.62 135 ± 24 144 ± 19 0.04
DBP, mm Hg 82 ± 12 82 ± 12 84 ± 11 0.41 79 ± 15 83 ± 11 0.24
Framingham Risk Scorea 6·3 ± 3·2 6·1 ± 3·4 6·7 ± 2·8 0.34 4·3 ± 4·0 6·6 ± 3·0 0.001
a Total cholesterol, LDL-C, HDL-C\\, triglycerides, NT-proBNP, and Framingham risk score were missing in 2 patients and hs-Troponin T was missing in 6 patients. Abbreviations: HRP,
high-risk plaque; CAD, coronary artery disease; NA, not applicable since no signiﬁcant differencewas found in type of chest pain in no CAD vs CAD (p= .133), thus no post-hoc testingwas
performed; LDL-C, low density lipoprotein cholesterol, HDL-C, high density lipoprotein cholesterol; hs-Troponin, high-sensitive Troponin; NT-proBNP: N-terminal pro brain natriuretic
peptide; eGFR, estimated glomerularﬁltration rate; CRP, C-reactive protein; ACE-inhibtor, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood
pressure; DBP: diastolic blood pressure.
112 M.J. Bom et al. / EBioMedicine 39 (2019) 109–1173.3. Proteomics analysis
Of all 358 proteins initially included for analysis, 26 had N20% of
cases below the lower limit of detection (Supplementary Table 1).
These proteins were excluded from further analysis. The total numberTable 2
CCTA results on a patient-basis.
CAC score
Median CAC score 170 [19–493]
Stenosis - no (%) a
No stenosis 26 (13%)
0–50% stenosis 27 (14%)
50–70% stenosis 53 (27%)
N70% stenosis 90 (46%)
Plaque analysis - no (%)
No atherosclerotic plaques 26 (13%)
Non-calciﬁed plaque 78 (40%)
Partially calciﬁed plaque 133 (68%)
Calciﬁed plaque 133 (68%)
Low attenuation plaque 57 (29%)
Positive remodeling 49 (25%)
Spotty calciﬁcation 27 (14%)
Napkin ring sign 20 (10%)
High-risk plaque 44 (22%)
Abbreviations: CCTA, coronary computed tomography angiography; CAC,
coronary artery calcium score.
a Stenosisgrade ofmost severe lesionswas used for patient-based analysisof proteins included for analysis on plaque morphology prediction
was 332.3.4. Protein signature associated with high-risk coronary lesions
A total number of 35 plasma proteins was predictive for the pres-
ence of CT-derived high-risk coronary lesions (Fig. 1 and Supplemen-
tary Table 3). The 11 most predictive proteins and the association of
protein levels with the presence of high-risk coronary lesions are illus-
trated in Fig. 1. A complete list of proteins associated with high-risk
plaques and the standardized mean protein levels in both groups is
provided in the Supplementary Table 2. The machine learning model
developed using biomarkers was found to have a high diagnostic
value for the presence of high-risk coronary lesions with an AUC of
0·79 ± 0.01 (Fig. 2). Using the same methodology, the clinical
model was computed. The relative importance of the variables in the
clinical model is shown in Supplementary Table 3. The clinical
model had only modest diagnostic accuracy and was inferior to our
biomarker model, with AUC of 0·65 ± 0·04 (p b 0·05). The combined
model, comprised of both clinical parameters and the identiﬁed
predictive biomarkers (AUC of 0·78 ± 0·02) also outperformed the
clinical model (p b 0·05). Relative importance of the variables in-
cluded in the combined model is shown in Supplementary Table 4.
All proteomic biomarkers were retained in the combined model, indi-
cating the incremental value of the identiﬁed biomarker panel for the
presence of high-risk plaque.
Fig. 1. Protein subset predictive for the presence of a high-risk plaque. The importance plot (left panel) illustrates the relative importance of all 35 plasma proteins predictive for the
presence of high-risk plaque. The spiderplot (right panel) depicts the 11 most important proteins in our machine learning model that differentiate between the presence (red) and
absence of high-risk plaque (green). The axes of the spiderplot represent the standarized mean protein levels (scaled zero-mean unit-variance). Standaridized mean levels of MMP12,
PLA2G7, TNFRSF10A, TRANCE, REN, TNFRSF13B, PRSS27, MEPE, and CD4 were higher in the high-risk plaque group compared to the non high-risk group. Conversely, TNFRSF10C and
SERPINA7 levels were lower in the high-risk group. Abbrevations of protein names are deﬁned in Supplementary Table 1.
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A different subset of 34 proteins was predictive for the absence of
CAD as visualized by CCTA (Fig. 3 and Supplementary Table 5). The 11
most predictive proteins and the association of protein levels with the
absence of CAD are illustrated in Fig. 3. An overview of all proteinsFig. 2. Diagnostic performance of the biomarker model versus the clinical model and the comb
with area under the curve (AUC) for the diagnostic performance of the clinical model (left), t
risk coronary artery disease. The mean ROC curve for each model is depicted by the blue line.
was outperformed by both the biomarker model (p b 0·05) and the combined model (p b 0·0predictive for the absence of coronary atherosclerosis and the standard-
ized mean protein levels in both groups is provided in Supplementary
Table 5. The machine learning biomarker model had a high diagnostic
accuracy for the identiﬁcation of patients with absence of CAD with an
AUC of 0·85 ± 0·05 (Fig. 4). The relative importance of the variables
in the clinical and combined model are shown in the Supplementaryined model for the presence of high-risk plaque. Receiver-operating characteristics curve
he biomarker model (middle) and the combined model (right) for the presence of high-
The grey shaded area represents the standard deviation of the curves. The clinical model
5).
Fig. 3. Protein subset predictive for CCTA-deﬁned absence of coronary atherosclerosis. Importance plot (left panel) illustrates the relative importance of all 34 plasma proteins predictive
for CCTA-deﬁned absence of coronary atherosclerosis. The spiderplot (right panel) depicts the 11 most important proteins in our machine learning model that differentiate between the
presence (red) and absence of coronary atherosclerosis (green). The axis of the spiderplot represents the standardized mean protein levels (scaled zero-mean unit-variance).
Standaridized mean levels of LEP and UMOD were higher in the absence of CAD group compared to the presence of CAD group. Conversely GDF-15, CCL24, CHIT1, REN, PLA2G7,
MMP12, OPG, TNFRSF9, and MB were lower in patients with absence of CAD. Abbrevations of protein names are deﬁned in Supplementary Table 1.
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value (AUC = 0·70 ± 0·04) and was outperformed by the proteomic
model (p b 0·05). The combined model also had greater diagnostic
accuracy than the clinical model with an AUC of 0·83 ± 0·04
(p b 0·05). All proteomic biomarkers were retained in the combined
model, indicating the incremental value of the identiﬁed biomarker
panel for the absence of CAD.Fig. 4. Diagnostic performance of the biomarker model versus the clinical model and the comb
curve with area under the curve (AUC) for the diagnostic performance of the clinical model (l
artery disease. The mean ROC curve for each model is depicted by the blue line. The grey
outperformed by both the biomarker model (p b 0·05) and the combined model (p b 0·05).4. Discussion
This study investigated the ability of a large set of biomarkers to
identify patients with either high-risk coronary plaque morphology or
absence of coronary atherosclerosis. Results show that a subset of 35
proteinswas highly predictive for the presence of high-risk coronary le-
sions. The diagnostic value of this biomarker signature was signiﬁcantlyined model for the absence of coronary atherosclerosis. Receiver-operating characteristics
eft), biomarker model (middle) and combined model (right) for the absence of coronary
shaded area represents the standard deviation of the curves. The clinical model was
115M.J. Bom et al. / EBioMedicine 39 (2019) 109–117greater than prediction with generally available clinical characteristics
and conventional biomarkers. Additionally, a distinct protein signature
of 34 plasma proteins was found to identify patients with absence of
coronary atherosclerosis.
4.1. Protein signature for the presence of high-risk plaques
Several studies have investigated the relationship between individ-
ual biomarkers and plaque morphology on invasive and non-invasive
imaging modalities [9,19,20]. Recent technical advances have enabled
the simultaneous measurement of large amounts of proteins and sev-
eral studies have used these novel techniques to investigate the ability
of large biomarker sets to identify patients with angiography-derived
signiﬁcant stenosis [21,22]. LaFramboise et al. studied the predictive
ability of 56 proteins for the presence of a coronary stenosis requiring
revascularization and found amodel that included osteopontin, resistin,
MMP7, and IFNγ to be highly predictive [22]. More recently, Ibrahim
et al. evaluated the combined predictive value of clinical variables and
109 candidate proteins. The ﬁnal model comprised several clinical vari-
ables and 4 biomarkers (midkine, adiponectin, apolipoprotein C-1, and
kidney injury molecule-1) and showed high accuracy for the presence
of angiography-derived stenosis. Although interesting from a diagnostic
point of view, these studies do not provide any information on the pre-
dictive value for the presence of high-risk coronary lesions.
Our study is the ﬁrst to assess the relationship between a large set of
biomarkers and high-risk plaque morphology using high-throughput
technology combined with state-of-the-art machine learning tech-
niques. Results show that a protein signature of 35 proteins, many of
which have not been linked with atherosclerosis previously, was highly
predictive for the presence of high-risk plaques (AUC = 0·79 ± 0·01).
A detailed description of the roles of themost important predictive pro-
teins is provided in the supplementary material. Notably, although sev-
eral predictive proteins identiﬁed by LaFramboise et al. and Ibrahim
et al. were also tested in our study (osteopontin, kidney injury
molecule-1, resistin, IFNy, and MMP7), none of these markers were in-
cluded in our biomarker model. However, it is important to note that
the predicted outcome in our study (high-risk plaque) was different
from these previous studies (angiographic CAD) and therefore the cur-
rent ﬁndings are not necessarily discordant with the aforementioned
studies.
For decades, risk prediction in clinical practice has been based on
generally available clinical characteristics. However, these clinical char-
acteristics, often combined into risk scores, have onlymodest predictive
value for coronary atherosclerosis and the occurrence of events [5].
More recently, improved cardiovascular risk algorithms have been pro-
posed using additional conventional biomarkers such as high-sensitive
troponin, NT-proBNP and CRP [6,8,23]. To test the validity of our ﬁnd-
ings, our biomarker model was tested against a model which included
generally available clinical characteristics and conventional biomarkers.
Results show that the biomarker model outperformed this clinical
model with AUCs of 0·79 ± 0.01 and 0·65 ± 0·04 respectively. Subse-
quently, to investigate the incremental value of the biomarker model to
clinical risk prediction, the clinicalmodelwas tested against a combined
model including both proteomic biomarkers and the generally available
clinical variables. The combined model (AUC of 0·78 ± 0·02) clearly
outperformed the clinical model. Since all proteomic biomarkers were
retained in the combinedmodel, the identiﬁed biomarker panel had in-
cremental value to generally available clinical characteristics and con-
ventional biomarkers for the prediction of high-risk plaques.
4.2. Protein signature for the absence of coronary artery disease
In addition to the protein signature for high-risk plaques, a different
subset of 34 proteins was found to be highly predictive of the CCTA-
deﬁned absence of CAD (AUC = 0·85 ± 0·05). The clinical model
(AUC = 0·70 ± 0·04) was clearly outperformed by the proteomicbiomarker model. Furthermore, the combined model for the absence
of CAD (AUC = 0·83 ± 0·04) also more accurately predicted the ab-
sence of CAD than the clinical model. Again, all proteomic biomarkers
were retained in the combined model, clearly demonstrating the incre-
mental value of the identiﬁed biomarker panel to clinical variables for
the prediction of the absence of CAD. A detailed description of the
roles of the most important predictive proteins is provided in the sup-
plementary material.
4.3. Common pathways in identiﬁed protein panels
Interestingly, in the top 11 biomarkers included in our biomarker
model for the presence of high-risk plaques (Fig. 1), we identiﬁed 7 pro-
teins associated with pro-inﬂammatory, pro-apoptotic pathways in
plaques. Number 1,metalloproteinase-12 (MMP12), a prominentmem-
ber of the senescence associated secretory phenotype, has been exten-
sively linked with inﬂammation, plaque stability and atherosclerotic
plaque burden [24,25]. Number 2, PLA2G7, also referred to as Lp-PLA2,
is an enzyme produced by inﬂammatory cells, leading to enhanced ath-
erosclerosis by increasing oxidation of LDL particles [26]. Numbers 3, 4,
5, and 8 TNFRSF10A, TNFRSF10C, TRANCE and TNFRS13B, are all in-
volved in the tumor necrosis factor (TNF) signaling pathway and play
a role in apoptosis, NFkB activation, and B-cell activation [27]. Number
10, surface CD4, is derived from the T-helper cells, which contribute to
the pro-inﬂammatory cross-talk between T-cells and macrophages
among other in the subendothelial compartment [28].
In the top 11 biomarkers for absence of coronary atherosclerosis
(Fig. 3), nine are associated with inﬂammatory pathways. Number 1,
GDF-15 (downregulated), a macrophage inhibitory cytokine, is higher
in inﬂammatory states and elevated GDF-15 levels are associated with
coronary plaque and occurrence of events [29]. Second, CCL24 (down-
regulated) contributes to recruitment of neutrophils and macrophages
and inhibition of CCL24 is shown to attenuate inﬂammatory activity in
pro-inﬂammatory disorders [30,31]. Third, chitotriosidase-1 (CHIT1),
an enzyme secreted by activated macrophages, has been shown to be
abundant in atherosclerotic plaques [32]. Interestingly, MMP12 and
PLA2G7 were also present in the panel predictive for high-risk plaques.
Closer exploration of the raw data revealed these proteins to be upreg-
ulated in the high-risk group but downregulated in the absence of CAD
(Figs. 1 and 3). In total, 6 proteins (i.e. MMP12, PLA2G7, renin, PRSS27,
SLAMF1, and TNFRSF9) were present in both protein signatures. All six
proteins showopposite regulation in the high-risk plaque versus the ab-
sence of CAD (Supplementary Tables 2 and 5), conﬁrming their poten-
tial biological involvement in plaque formation. Number 9 and 10,
osteoprotegerin (OPG) and TNFRSF9, are both members of the TNF re-
ceptor family. OPG (downregulated) is reported to harbor protective ef-
fect by serving as decoy receptor for receptor-activator of nuclear factor
kappa-B ligand and as inhibitor of vascular calciﬁcation [27,33]. How-
ever, several studies have associated elevated OPG levels with cardio-
vascular events [34]. TNFRSF9 (downregulated) plays a key role in
activating pro-inﬂammatory T-helper cells and is implicated in the pro-
gression of atherosclerosis [35].
Upon integration of the ‘high-risk plaque’ and ‘absence of CAD’ sig-
natures, a concept emerges of a systemically quantiﬁable hyperactivity
of pro-inﬂammatory signaling cascades involved in T-cell, macrophage,
apoptotic activity, and cellular recruitment in case of the presence of
high-risk plaques. Conversely, there is hypo-activity of these signaling
pathways in case of absence of coronary atherosclerosis.
4.4. Clinical implications and future perspectives
Despite recent advances in lipid-lowering therapies, patients with
CAD remain at substantial risk for coronary events [36]. Elevated levels
of biomarkers of vascular inﬂammation such as CRPhave been proposed
to indicate the extent of residual risk in these patients. The promise of
this concept was recently conﬁrmed by the CANTOS trial which showed
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targeting interleukin-1β reduced the rate of cardiovascular events inde-
pendent of lipid-level lowering [37]. These ﬁndings may be seen as a
ﬁrst step towards patient-tailored management in CAD patients, in
which phenotyping of both residual lipid- and inﬂammatory-driven
risk help guide therapeutic choices [38]. Given the non-speciﬁc nature
of CRP, there is a need for more speciﬁc markers of the inﬂammatory
processes in the arterial wall. Technical advances in proteomic analyses
paralleled by advances in machine learning have paved the way for the
introduction of proteomics. Given the relatively low costs compared to
CCTA and routine laboratory testing of single biomarkers, and the
rapid analysis of proteomic samples (within 24 h), targeted proteomics
offers the opportunity to be highly cost-effective. Ganz et al. recently
demonstrated the ability of targeted proteomics, measured using mod-
iﬁed aptamers, to identify patients at risk for cardiac events [39]. Given
the limited patient population in our study cohort, validation with clin-
ical events was not possible. Alternatively, we opted to investigate the
predictive value of targeted proteomics for CCTA-deﬁned high-risk cor-
onary lesions and absence of coronary atherosclerosis. Since multiple
studies have conﬁrmed the link between CT-derived high-risk plaques
and cardiovascular events [1,2] and conversely between the absence
of CAD and event-free survival [40,41], prognostic implication of both
identiﬁed protein signatures seems plausible. Of course, our results
must be seen as hypothesis-generating and validation in external co-
horts with clinical events is necessary for clinical application. Hypothet-
ically, identiﬁcation of high-risk patients could help guide the use of
expensive medication to the highest risk groups, with the promise of
shedding light on the predominant risk factors in these patients (lipid,
inﬂammation, thrombosis). Conversely, identiﬁcation of patients with-
out coronary atherosclerosis could help avoid overtreatment. Impor-
tantly, to conﬁrm the prognostic value of the two protein signatures,
prospective validation in outcome studies is warranted. If conﬁrmed,
this may herald the introduction of targeted proteomics in the cardio-
vascular arena.
4.5. Limitations
Several aspects may need closer attention. First, the current report is
a substudy of the PACIFIC trial and although blood samples were pro-
spectively drawn and stored for analysis, the current report has a lim-
ited sample size and the analysis should be considered retrospective
in nature. Second, external validation of our ﬁndings in a separate vali-
dation cohort was not possible due to the relatively small sample size.
To minimize the risk of overﬁtting, state-of-the-art machine learning
modelling was performed best suited to the nature of the data and the
limited sample size. A rigorous stability selection procedure and special-
ized regularization strategy were used to ensure reliability of our ﬁnd-
ings. Subsequently, biomarker signatures were internally validated in
the current cohort to avoid over-ﬁtting, by using a 10-fold stratiﬁed
cross-validation over the training partition of the data (80%) while the
remaining 20% was used as the testing dataset. For increased conﬁ-
dence, this procedure was repeated multiple times on a reshufﬂed
dataset. Although we believe these techniques corroborate the validity
of our ﬁndings, external validation in larger cohorts is mandatory to
conﬁrm the predictive value of the identiﬁed biomarker subsets. Simi-
larly, validation with coronary events was not possible in this cohort
due to the relatively small sample size. Instead, the presence of
high-risk plaque was used as a surrogate for coronary events. It must
however be noted that although high-risk plaque has been extensively
associatedwith adverse outcome, not all high-risk plaques cause events
[1,2,14]. Validation with coronary events in an external cohort is there-
fore crucial to validate our ﬁndings. Third, our study population
consisted of symptomatic patientswith intermediate risk of CAD. There-
fore, our predictionmodelmay be less suitable for subjects in a low-risk,
primary prevention cohort. Fourth, our predictivemethodology focused
on the performance of the developedmachine learningmodel involvinga joint panel of selected biomarkers which together, as a group, lead to
reliable prediction. This is a crucial difference in comparison with uni-
variate models that evaluate the up- or downregulation of single pro-
teins. Contribution of all proteins included in the joint panel is needed
to obtain a reliable prediction model. Our study therefore does not pro-
vide deﬁnite information on the up- or downregulation of single pro-
teins. Last, since some of the included proteins have not been
implicated in the pathophysiology of atherosclerosis before, further
studies are warranted to elucidate their role in atherogenesis.
5. Conclusions
Using statistical machine learning models, trained on targeted
plasma proteomics, we deﬁned two complementary protein signatures:
one for the identiﬁcation of patients with high-risk coronary lesions and
one for the identiﬁcation of patients with absence of coronary athero-
sclerosis. Both biomarker subsetswere shown to be superior to generally
available clinical characteristics and conventional biomarkers in
predicting presence or absence of (high-risk) coronary atherosclerosis.
These promising ﬁndings warrant external validation of the value of
targeted proteomics to identify cardiovascular risk in cardiovascular
outcome studies.
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